Palatable oral suspension and method
A drug formulation in the form of a dry powder is provided which when mixed with water forms a palatable oral suspension substantially free of bitter taste, the dry powder being formed of a drug, preferably des-quinolone, which in solution has a bitter taste, and a pH modifying agent which is preferably an alkaline material such as L-arginine, where upon mixing the dry-powder in water causes the drug to have reduced solubility or precipitate in-situ to form a palatable oral suspension essentially free of bitter taste. An oral suspension, methods for making same and a method for masking the bitter taste of drugs employing one or more pH modifying agents are also provided.
1. A pharmaceutical composition in the form of an oral suspension of a normally unpalatable acidic drug, which is a quinolone-carboxylic acid derivative or a salt thereof or a naphthyridone carboxylic acid derivative or a salt thereof, which suspension is substantially devoid of bitter taste, which comprises particles of a readily soluble acidic drug which in solution has a bitter taste, and water for oral suspension, and one or more alkaline pH modifying agents mixed with the particles of drug which renders and maintains the drug in substantially insoluble form in the oral suspension, so that the bitter taste of the drug is masked without the use or need for polymer or wax coatings or microencapsulation wherein the pH modifying agents adjusts suspension pH to cause reduction in solubility or in-situ precipitation of the drug in the suspension.
2. The pharmaceutical composition as defined in claim 1 wherein the drug is a quinolone-carboxylic acid derivative or a salt thereof.
3. The pharmaceutical composition as defined in claim 1 wherein the drug is
1 -cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-5-isoindolyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate monohydrate (des-quinolone).
4. The pharmaceutical composition as defined in claim 1 wherein the acidic drug is des-quinolone, norfloxacin, ciprofloxacin or ofloxacin.
5. The pharmaceutical composition as defined in claim 1 wherein said alkaline agent is one or more selected from the group consisting of L-arginine, L-lysine, sodium citrate and magnesium hydroxide.
6. The pharmaceutical composition as defined in claim 1 wherein said composition further optionally includes one or more antioxidants, glidants, and/or suspending agents.
7. The pharmaceutical composition as defined in claim 1 comprising from about 10 mg to about 600 mg (per 5 ml of suspension) of readily water-soluble acidic drug, from about 3 mg to about 200 mg of an alkaline pH modifying agent, and sufficient amount of water to provide 5 ml of suspension.
8. The pharmaceutical composition as defined in claim 1 in the form of an oral suspension comprising per 5 ml of constituted suspension, which comprises
drug in an amount within the range from about 10 mg to about 600 mg,
pH modifying agent in an amount within the range from about 3 mg to about 200 mg,
antioxidant in an amount within the range from about 0 to about 20 mg,
glidant in an amount within the range from about 0 to about 100 mg,
suspending agent in an amount within the range from about 0 to about 24 mg, and
water as necessary to provide 5 ml of constituted suspension.
9. The pharmaceutical composition as defined in claim 8 wherein the drug is
1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-5-isoindolyl]-4 -oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate monohydrate, the pH modifying agent is L-arginine, the antioxidant is sodium bisulfite, the glidant is silicon dioxide and the suspending agent is sodium carboxymethyl cellulose.
10. A method for preparing an oral suspension of a drug which is substantially free of bitter taste, which comprises providing a readily water soluble drug which in solution has a bitter taste, which drug is a quinolone-carboxylic acid derivative or a salt thereof or a naphthyridone carboxylic acid derivative or a salt thereof, mixing the drug with a one or more alkaline pH modifying agents capable of generating an environment in water which causes reduction in solubility or in-situ precipitation of the drug, and mixing the drug and alkaline pH modifying agents with water to form an oral suspension which is essentially free of bitter taste, without the use or need for polymer or wax coating or microencapsulation.
11. A method for masking the bitter taste or otherwise unpalatable taste of a water-soluble drug for oral administration, which comprises providing a readily water-soluble drug in particulate form, which drug is a quinolone-carboxylic acid derivative or a salt thereof or a naphthyridone carboxylic acid derivative or a salt thereof, mixing the drug with one or more alkaline pH modifying agents, and water, whereby the pH modifying agent provides a pH environment which renders and maintains the drug substantially insoluble in suspension so that the bitter taste of the drug is masked and/or substantially reduced, upon oral administration, without the use or need for polymer or wax coatings or microencapsulation.
12. The method as defined in claim 11 wherein said drug is des-quinolone and the pH modifying agent is selected from the group consisting of L-arginine, L-lysine, sodium citrate and magnesium hydroxide.
13. An oral suspension of des-quinolone
comprising des-quinolone,
a pH modifying agent,
optional excipients
and water for suspension,
the des-quinolone being rendered and maintained substantially insoluble in the water for suspension, whereby the oral suspension is substantially free of bitter taste without the use or need for polymer or wax coating or microencapsulation.